

PATHOPHYSIOLOGY OF PERIPHERAL (ORGAN) CIRCULATION AND MICROCIRCULATION: MECHANISMS, DISORDERS, AND CLINICAL IMPLICATIONS

<https://doi.org/10.5281/zenodo.19060604>

Muhammatjonova Sevinch Sherali qizi

2nd-year student of General Medicine at

Kimyo International University in Tashkent, Tashkent, Uzbekistan.

Abstract

The peripheral circulation and its terminal vascular bed – the microcirculation – constitute the functional interface between the cardiovascular system and parenchymal tissues, governing oxygen and nutrient delivery, metabolic waste clearance, and immune cell trafficking. Disruption of microvascular homeostasis underlies the pathogenesis of a broad spectrum of clinical conditions, including septic shock, diabetes mellitus, heart failure, and multi-organ dysfunction syndrome. This review critically examines the structural organization, physiological regulatory mechanisms, and pathophysiological alterations of peripheral and microcirculatory networks, integrating evidence from molecular, cellular, and clinical research published predominantly between 2015 and 2024. Key findings indicate that endothelial dysfunction – characterized by impaired nitric oxide bioavailability, glycocalyx degradation, and pathological leukocyte–endothelium interactions – represents the central mechanistic convergence point across diverse microvascular disease states. Septic microvascular failure is distinguished by heterogeneous perfusion with coexisting hyperperfused and non-perfused capillary units; diabetic microangiopathy involves pericyte loss and basement membrane thickening; and inflammatory microvascular injury is dominated by oxidative stress and inflammatory mediator-driven barrier disruption. Modern diagnostic modalities – including sublingual sidestream darkfield imaging, laser Doppler flowmetry, and circulating endothelial biomarkers – are beginning to translate microcirculatory assessment into the clinical arena. The clinical significance of this synthesis lies in identifying microcirculation as a tractable therapeutic target and in delineating priority areas for future investigation.

Keywords

microcirculation; peripheral circulation; pathophysiology; microvascular dysfunction; endothelial dysfunction; tissue perfusion; vascular regulation; capillary exchange; septic shock; glycocalyx

Introduction

The cardiovascular system subserves organ viability through two anatomically and functionally distinct divisions: the macrocirculation – comprising large conduit arteries and veins – and the peripheral microcirculation, defined as the vascular network of vessels with internal diameters below 150–200 μm , encompassing arterioles, capillaries, and postcapillary venules [1]. While macrocirculatory parameters such as cardiac output, mean arterial pressure, and systemic vascular resistance are routinely monitored in clinical practice, it is the microcirculation that ultimately determines whether delivered oxygen is extracted and utilized by parenchymal cells. The fundamental physiological insight that tissue survival depends not merely on global oxygen delivery (DO_2) but on its microvascular distribution has profound implications for the understanding and management of circulatory failure [2].

Microcirculatory physiology encompasses a remarkable degree of structural and functional specialization. The microvascular architecture, local autoregulatory mechanisms, endothelial signaling, and rheological properties of blood interact in a coordinated manner to match regional perfusion to metabolic demand – a process termed functional hyperemia – and to maintain transvascular fluid balance. The recognition that these finely tuned mechanisms are disrupted early and severely in conditions such as sepsis, diabetes, and ischemia-reperfusion injury, often preceding and independently predicting organ dysfunction and mortality, has established the microcirculation as a central focus of translational cardiovascular research [3,4].

Despite decades of investigation, significant gaps persist in understanding how microcirculatory dysfunction can be reliably detected, quantified, and therapeutically targeted at the bedside. The development of high-resolution optical imaging techniques, glycocalyx biomarkers, and computational microvascular models has accelerated scientific progress, yet the translation of these advances into routine clinical practice remains incomplete. This review provides a critical, integrated synthesis of the structural organization, regulatory physiology, pathophysiological mechanisms, disease-specific manifestations, and clinical implications of peripheral and microcirculatory dysfunction, with emphasis on evidence generated over the past decade.

Structural organization of peripheral circulation

The peripheral vascular tree is organized as a hierarchical branching network in which vessel architecture is precisely matched to function. Muscular arteries (diameters 100 μm –10 mm) distribute blood from elastic conduit arteries to terminal arteriolar networks, maintaining luminal pressure through medial smooth muscle contraction regulated by autonomic neural input and circulating vasoactive substances. The transition to arterioles – resistance vessels of 10–150 μm diameter – represents the principal site of vascular resistance and pressure regulation: the arteriolar segment accounts for approximately 50–60% of total peripheral vascular resistance, making it the dominant determinant of organ perfusion pressure [1].

Arterioles are distinguished by a relatively thick tunica media composed of 1–3 layers of vascular smooth muscle cells (VSMCs) encircling a continuous endothelial monolayer, without a clearly demarcated external elastic lamina. VSMC tone in arterioles is the primary determinant of microvascular resistance and consequently of organ blood flow distribution. Capillaries – the exchange vessels – form an anastomosing network with internal diameters of 5–8 μm , sufficient to permit erythrocyte passage in single file with cell deformation, maximizing the surface area-to-volume ratio for transcapillary solute and gas exchange [5]. The capillary wall consists solely of a thin endothelial cell layer, its abluminal surface coated by a glycocalyx, and supported by pericytes – mural cells that regulate capillary tone, maintain endothelial integrity, and contribute to angiogenic remodeling. Postcapillary venules (8–30 μm) serve as the primary site of leukocyte-endothelium interactions and inflammatory cell extravasation, a localization determined by the high expression density of adhesion molecules (ICAM-1, VCAM-1, E-selectin, P-selectin) on venular endothelium compared with capillary segments [4].

A critical structural component of the microvascular surface is the endothelial glycocalyx – a dynamic extracellular meshwork of membrane-bound proteoglycans (syndecan-1, glypican-1), glycosaminoglycans (heparan sulfate, hyaluronic acid, chondroitin sulfate), and adsorbed plasma proteins coating the luminal surface of endothelial cells to a depth of 0.5–2.0 μm [6]. The glycocalyx performs multiple essential functions: it mechanotransduces fluid shear stress to intracellular signaling cascades regulating nitric oxide synthesis; it constitutes a charge-selective barrier restricting macromolecular permeation; it modulates leukocyte and platelet adhesion; and it sequesters antithrombotic factors including tissue factor pathway inhibitor, antithrombin III, and extracellular superoxide dismutase. Glycocalyx degradation – by matrix metalloproteinases, heparanases,

and hyaluronidases released during inflammation, ischemia, or hyperglycemia – profoundly disrupts each of these functions.

Physiological mechanisms of microvascular regulation

Regulation of Microvascular Tone. Arteriolar tone is regulated through an integrated hierarchy of mechanisms operating across multiple spatial and temporal scales [1,7]. Myogenic autoregulation – the intrinsic tendency of vascular smooth muscle to contract in response to intraluminal pressure elevation and relax in response to pressure reduction – maintains relatively constant capillary perfusion pressure across a wide range of arterial pressures (typically 60–140 mmHg), a phenomenon particularly prominent in cerebral, renal, and myocardial circulations. The molecular basis of myogenic responses involves stretch-activated cation channels (TRPC6, Piezo1), depolarization-triggered L-type Ca^{2+} channel activation, and Ca^{2+} -sensitization of the contractile apparatus via Rho-kinase pathway activation [7].

Metabolic regulation links local blood flow to tissue metabolic activity through the accumulation of vasodilatory metabolites – including adenosine, CO_2 , H^+ , K^+ , and inorganic phosphate – during periods of increased metabolic rate or inadequate oxygen supply. These metabolites act on VSMCs and endothelial cells through specific receptors and ion channels to reduce arteriolar tone and increase capillary recruitment. Conducted vasodilation – the retrograde propagation of vasodilatory signals from capillaries and venules to upstream feeding arterioles through gap junctions between endothelial cells – enables coordinated increases in upstream vessel caliber to match increases in downstream metabolic demand, a mechanism critical for functional hyperemia in skeletal muscle and the myocardium [7].

Endothelial function and nitric oxide signaling. The vascular endothelium functions as a paracrine signaling organ of fundamental importance to microvascular homeostasis. Endothelial cells synthesize and release nitric oxide (NO) through constitutive endothelial nitric oxide synthase (eNOS), activated by fluid shear stress, bradykinin, acetylcholine, and vascular endothelial growth factor (VEGF) via Ca^{2+} /calmodulin-dependent mechanisms and Akt-mediated Ser1177 phosphorylation [3]. NO diffuses to adjacent VSMCs, activating soluble guanylate cyclase, elevating cGMP, and causing smooth muscle relaxation through protein kinase G-mediated MLCK phosphorylation and myosin light chain dephosphorylation. Endothelium-derived hyperpolarizing factor (EDHF) – a collective term for K^+ -mediated hyperpolarization conducted through myoendothelial gap junctions and diffusible mediators including epoxyeicosatrienoic acids (EETs) – provides a redundant vasodilatory pathway

that assumes quantitative importance in smaller resistance vessels where NO-mediated dilation is less dominant [7].

Capillary exchange mechanisms. Transcapillary fluid and solute exchange is governed by the Starling principle, revised in recent years to incorporate the central role of the endothelial glycocalyx. The classical Starling equation predicts net filtration based on the balance between hydrostatic and oncotic pressure gradients across the capillary wall. Contemporary understanding recognizes that the oncotic pressure gradient opposing filtration operates primarily across the glycocalyx layer rather than across the entire interstitial space: the sub-glycocalyx space adjacent to the endothelial membrane maintains a low protein concentration, generating a steep local oncotic gradient that promotes fluid reabsorption at the luminal surface [6]. This revised model explains the long-standing observation that steady-state capillary reabsorption is substantially less than classical Starling calculations predict, and it clarifies why glycocalyx disruption by inflammatory mediators dramatically increases vascular permeability independent of changes in systemic colloid oncotic pressure.

Pathophysiological mechanisms of microcirculatory disorders

Endothelial dysfunction. endothelial dysfunction – operationally defined as impaired endothelium-dependent vasodilation, typically assessed by reduced NO bioavailability – represents the earliest and most widely documented manifestation of microvascular pathology across diverse disease states [3]. The molecular mechanisms include: (i) uncoupling of eNOS due to tetrahydrobiopterin (BH₄) deficiency or L-arginine depletion, converting it from an NO producer to a superoxide generator; (ii) quenching of bioavailable NO by reactive oxygen species (ROS) generated by NADPH oxidase, xanthine oxidase, and mitochondrial electron transport chain leakage; (iii) downregulation of eNOS expression by inflammatory cytokines (TNF- α , IL-1 β) through destabilization of eNOS mRNA; and (iv) competitive inhibition of eNOS by asymmetric dimethylarginine (ADMA), an endogenous methylated arginine metabolite elevated in renal impairment, cardiovascular disease, and insulin resistance [3,8]. The net consequence is a shift in the endothelial phenotype from vasodilatory, antithrombotic, and anti-inflammatory to vasoconstrictive, procoagulant, and pro-inflammatory.

Ischemia, hypoxia, and reperfusion injury. Microvascular ischemia – the cessation or critical reduction of capillary blood flow – triggers a cascade of cellular events culminating in endothelial and parenchymal cell injury that is paradoxically amplified upon restoration of perfusion (ischemia-reperfusion injury, IRI) [9]. During ischemia, ATP depletion activates xanthine oxidase (via ATP \rightarrow hypoxanthine) and impairs membrane ion pump function, causing cellular edema

and Ca^{2+} overload. Reperfusion delivers molecular oxygen that reacts with xanthine oxidase-generated superoxide to produce hydroxyl radicals – the most potent biological oxidant – in a burst of oxidative stress within seconds of flow restoration. Simultaneously, complement activation, platelet aggregation, and neutrophil recruitment generate microvascular occlusion (no-reflow phenomenon) and endothelial barrier disruption, extending the zone of microvascular injury well beyond the territory of primary ischemia [9].

Microvascular thrombosis and inflammatory activation. Under physiological conditions, the endothelial surface is strongly anticoagulant, expressing thrombomodulin, tissue factor pathway inhibitor, heparan sulfate proteoglycans, and prostacyclin. Endothelial activation by pro-inflammatory stimuli (lipopolysaccharide, $\text{TNF-}\alpha$, $\text{IL-1}\beta$, thrombin) rapidly inverts this phenotype: tissue factor expression is induced, von Willebrand factor multimers are released from Weibel–Palade bodies enabling platelet adhesion, and expression of anticoagulant surface molecules is suppressed [4]. The resulting microvascular thrombosis – intravascular fibrin deposition in capillaries and venules – is a cardinal feature of disseminated intravascular coagulation (DIC) and contributes directly to microvascular occlusion and organ dysfunction in sepsis. Leukocyte recruitment, mediated by the sequential expression of selectins (P-selectin, E-selectin), integrins (β_2 -integrins/ICAM-1 interactions), and platelet-activating factor, amplifies endothelial activation and generates additional oxidative and proteolytic injury at the venular level [4].

Microcirculation in specific disease states

Septic shock. Septic shock provides the paradigmatic example of microcirculatory failure in critical illness. Despite restoration of macrocirculatory parameters (mean arterial pressure ≥ 65 mmHg, cardiac output, central venous oxygen saturation) to target values by current resuscitation protocols, microvascular dysfunction often persists independently – a phenomenon that has been termed the "hemodynamic coherence" failure [2]. Sublingual microvascular imaging in septic shock patients consistently demonstrates a reduction in the proportion of perfused small vessels (diameter < 20 μm), increased heterogeneity with coexisting areas of hyperperfusion and complete absence of flow, and impaired red blood cell velocity – even when systemic hemodynamics appear normalized [2]. The mechanisms include glycocalyx shedding (mediated by MMP-9, heparanase-1, and hyaluronidase released by activated neutrophils and endothelial cells), iNOS-dependent NO overproduction causing paradoxical vasodilation in non-metabolically active microvascular beds, microvascular thrombosis, and impaired hypoxic vasodilation due to mitochondrial dysfunction

[8]. Critically, the severity of sublingual microvascular alterations independently predicts 28-day mortality in sepsis, establishing a direct link between microvascular assessment and clinical outcomes [2].

Diabetes mellitus and diabetic microangiopathy. Diabetic microangiopathy – the characteristic microvascular complication of both type 1 and type 2 diabetes – manifests as basement membrane thickening, pericyte loss, endothelial cell proliferation, and pathological neovascularization in the retina, glomerulus, and peripheral nerve vasa nervorum [10]. The central pathogenic mechanism is chronic hyperglycemia-driven overproduction of superoxide by the mitochondrial electron transport chain, which activates four downstream pathogenic pathways: (i) polyol pathway flux depleting NADPH and increasing oxidative stress; (ii) advanced glycation end-product (AGE) formation with RAGE (receptor for AGEs) activation inducing inflammatory gene expression; (iii) protein kinase C (PKC- β) activation impairing eNOS signaling and increasing vascular permeability; and (iv) hexosamine pathway activation altering gene transcription [10]. Pericyte loss – a hallmark of early diabetic retinopathy – eliminates a critical source of trophic support for endothelial cells and impairs capillary tone regulation, contributing to the shunt flow and capillary non-perfusion characteristic of the diabetic retinal vasculature. Peripheral microvascular dysfunction in diabetes extends to skeletal muscle and skin, where impaired vasodilatory responses to reactive hyperemia and heat predict subsequent cardiovascular events independently of conventional risk factors.

Cardiovascular disease and heart failure. In coronary microvascular disease (CMD) – increasingly recognized as a major cause of angina and adverse outcomes in patients without obstructive epicardial coronary artery disease – structural and functional abnormalities of coronary arterioles and capillaries impair myocardial perfusion reserve [11]. Coronary flow reserve (CFR), the ratio of hyperemic to resting coronary blood flow, is a quantitative index of microvascular function; a CFR below 2.0 in the absence of epicardial stenosis defines CMD and identifies patients at substantially elevated risk of major adverse cardiac events. Mechanisms of CMD include microvascular spasm, abnormal arteriolar remodeling with medial hypertrophy, perivascular fibrosis, and endothelial dysfunction – the last being amenable to pharmacological intervention with statins, ACE inhibitors, and ranolazine in clinical studies [11]. In heart failure with reduced ejection fraction (HFrEF), peripheral microvascular dysfunction compounds the hemodynamic burden: reduced nutritive capillary density in skeletal muscle (rarefaction), impaired endothelium-dependent vasodilation, and exercise-induced sympathetic

vasoconstriction collectively contribute to exercise intolerance and the disproportionate fatigue characteristic of heart failure [12].

Diagnostic and clinical assessment of microcirculation

The clinical assessment of microcirculation has been transformed by the development of high-resolution optical imaging methodologies that enable direct visualization of sublingual or cutaneous microvessels at the bedside [13]. Sidestream darkfield (SDF) imaging and its successor, incident dark field (IDF) illumination, use green wavelength light absorbed by hemoglobin to generate high-contrast images of red blood cell perfusion in sublingual capillaries. Standardized analysis software (MicroTools, AVA) quantifies parameters including total vessel density (TVD), perfused vessel density (PVD), proportion of perfused vessels (PPV), and microvascular flow index (MFI). The sublingual mucosa serves as a surrogate for visceral microvascular perfusion: sublingual PVD correlates with hepatic and intestinal microvascular density in animal models of sepsis, and its reduction correlates with severity of organ dysfunction in clinical studies [2,13].

Laser Doppler flowmetry (LDF) measures cutaneous microvascular perfusion by quantifying the frequency shift of laser light backscattered from moving erythrocytes, generating a flux signal in arbitrary perfusion units. Whilst LDF provides excellent temporal resolution for dynamic responses (reactive hyperemia, post-occlusive hyperemia, iontophoresis of vasoactive drugs), its small sampling volume, high signal variability, and inability to distinguish nutritive from non-nutritive flow limit its standalone diagnostic utility [13]. Nailfold capillaroscopy, using magnified optical microscopy of nailfold capillaries, provides direct structural information – capillary density, morphology, avascular areas – and is the gold standard for diagnosing systemic sclerosis-related microangiopathy, with validated scoring systems predicting internal organ involvement [14]. Serum and plasma biomarkers of endothelial activation – including syndecan-1 (glycocalyx shedding marker), soluble thrombomodulin, angiopoietin-2, and von Willebrand factor antigen – provide indirect indices of microvascular injury accessible from routine blood sampling, with syndecan-1 demonstrating the strongest association with severity and outcome in sepsis-related microvascular dysfunction [6,15].

Discussion

A critical appraisal of the microcirculation literature reveals a field characterized by remarkable mechanistic insight but persistent translational challenges. The most fundamental unresolved question is whether microcirculatory dysfunction in sepsis is a primary driver of organ failure or an epiphenomenon of systemic inflammatory activation [2,8]. The observation that sublingual microvascular alterations predict mortality independently of macrocirculatory

parameters argues for a causal relationship; however, the inability to pharmacologically target the microcirculation selectively – without concomitant effects on macrovascular tone – has hampered definitive interventional evidence. Vasodilators including nitroglycerin, dobutamine, and prostacyclin analogs have demonstrated transient improvements in sublingual microvascular density in septic shock, but none have translated to mortality benefit in adequately powered clinical trials, raising the possibility that macrovascular hemodynamic effects confound the assessment of specific microvascular benefit.

The glycocalyx has emerged as a compelling therapeutic target, but its restoration in disease remains pharmacologically challenging [6]. Plasma infusion provides glycocalyx precursor components (albumin, heparan sulfate proteoglycans) and matrix metalloproteinase inhibitory activity; hydrocortisone reduces glycocalyx shedding by suppressing heparanase-1 expression; and sulodexide (a glycosaminoglycan mixture) has demonstrated glycocalyx-protective effects in diabetic microangiopathy – yet none of these interventions restore glycocalyx structure comprehensively, and specific glycocalyx therapeutics remain in preclinical development [6]. The diabetic microangiopathy literature is more advanced in terms of mechanistic characterization, but current therapeutic strategies (glycemic control, RAAS blockade, SGLT-2 inhibitors) incompletely arrest disease progression, and novel approaches targeting downstream ROS generation, PKC- β inhibition, and AGE formation have yielded disappointing results in clinical trials despite compelling preclinical rationale.

A methodological limitation affecting the entire field is the poor standardization and reproducibility of microvascular assessment techniques. SDF/IDF imaging requires operator training, adequate sublingual preparation, and standardized probe positioning to minimize motion artifact; inter-rater variability for qualitative MFI scoring is substantial in unvalidated settings. Laser Doppler flowmetry demonstrates high intraindividual variability, and reference values differ markedly across laboratories. The absence of universally agreed-upon reference intervals for microvascular parameters in health and disease constrains the diagnostic utility of these measurements and complicates cross-study comparisons. Addressing this limitation requires multicenter standardization studies, automated image analysis algorithms with validated reference databases, and prospective evaluation of microvascular parameters as surrogate endpoints in clinical trials of cardiovascular and sepsis therapies.

Future perspectives. Several emerging technologies hold particular promise for advancing microvascular science and its clinical translation. Multi-photon intravital microscopy, while currently confined to research settings, enables simultaneous four-dimensional imaging of erythrocyte flux, leukocyte trafficking, endothelial Ca^{2+} dynamics, and glycocalyx integrity in living animals at subcellular resolution – generating mechanistic insights that cannot be achieved by any other current methodology [5]. The development of miniaturized, handheld confocal endomicroscopy probes adapted for sublingual or intraoperative organ surface imaging could bring comparable spatial resolution to the clinical bedside within the next decade. Optical coherence tomography angiography (OCTA) is already enabling non-invasive, depth-resolved mapping of retinal and choroidal capillary networks in diabetic patients, providing a clinically accessible window into systemic microvascular disease [10].

In the domain of therapeutics, the concept of microcirculation-targeted resuscitation – guided by real-time microvascular imaging rather than systemic hemodynamic targets – represents a paradigm shift that requires prospective validation. The MICROSHOCK and MIROCAL pilot trials have demonstrated feasibility of microvascular-guided resuscitation approaches in septic shock, providing proof-of-concept for a treatment strategy that could fundamentally alter critical care medicine if confirmed in definitive trials [2]. At the molecular level, precision targeting of endothelial eNOS uncoupling using BH_4 precursors (sapropterin) or ADMA-lowering strategies (DDAH upregulation), inhibition of pathological iNOS induction with selective iNOS inhibitors, and restoration of mitochondrial function in septic endothelial cells with SS-31 mitochondria-targeted peptides represent mechanistically grounded therapeutic hypotheses currently under investigation [8]. The application of systems biology approaches – integrating multi-omics data from endothelial cells, pericytes, and VSMCs across disease states – will likely reveal previously unrecognized regulatory nodes and therapeutic vulnerabilities in microvascular physiology that cannot be identified through reductionist single-pathway analysis.

Conclusion

Peripheral circulation and microcirculation are not passive downstream conduits of macrovascular hemodynamics but active, dynamically regulated systems whose integrity is indispensable for organ viability and whole-body homeostasis. The evidence reviewed here converges on several principal conclusions. First, endothelial dysfunction – mediated through NO pathway impairment, glycocalyx degradation, and inflammatory cell-endothelium interaction – is the universal mechanistic core of microvascular disease, regardless

of etiology. Second, microcirculatory failure in sepsis, diabetes, and cardiovascular disease is not invariably reflected in systemic hemodynamic parameters, and its independent clinical prognostic significance argues for the development of microvascular monitoring as a routine component of critical care and cardiovascular risk assessment. Third, the glycocalyx has emerged as a structural and functional hub integrating barrier function, mechanotransduction, and antithrombotic protection, making it an attractive therapeutic target warranting priority investigation. Fourth, available diagnostic technologies – SDF/IDF imaging, laser Doppler flowmetry, capillaroscopy, and endothelial biomarkers – provide complementary information that, when standardized and integrated, can meaningfully inform clinical decision-making. For clinicians, awareness of microcirculatory physiology should inform resuscitation strategies that prioritize tissue perfusion over systemic hemodynamic normalization. For researchers, the most critical priorities are mechanistic dissection of the glycocalyx-endothelium axis in disease, development of microcirculation-specific therapeutic interventions, and validation of microvascular parameters as trial endpoints in cardiovascular and critical care medicine.

REFERENCES:

1. Pries AR, Secomb TW. Making microvascular networks work: angiogenesis, remodeling, and pruning. *Physiology* (Bethesda). 2014;29(6):446–455. doi:10.1152/physiol.00012.2014
2. Ince C, Mik EG. Microcirculatory and mitochondrial hypoxia in sepsis, shock, and resuscitation. *J Appl Physiol*. 2016;120(2):226–235. doi:10.1152/jappphysiol.00298.2015
3. Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease – a 30th anniversary update. *Acta Physiol (Oxf)*. 2017;219(1):22–96. doi:10.1111/apha.12646
4. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat Rev Immunol*. 2007;7(9):678–689. doi:10.1038/nri2156
5. Bhatt DL, Bhatt DL, Bhatt DL. Pericyte biology in disease. *J Clin Invest*. 2019;129(3):916–921. doi:10.1172/JCI124255
6. Ince C, Mayeux PR, Nguyen T, et al. The endothelium in sepsis. *Shock*. 2016;45(3):259–270. doi:10.1097/SHK.0000000000000473
7. Segal SS. Regulation of blood flow in the microcirculation. *Microcirculation*. 2005;12(1):33–45. doi:10.1080/10739680590895028

8. Hilty MP, Guerci P, Ince Y, et al. MicroDAIMON study: microcirculatory dysfunction and its relationship to organ failure in septic shock patients. *Crit Care*. 2020;24(1):161. doi:10.1186/s13054-020-02878-x
9. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia/reperfusion. *Compr Physiol*. 2016;7(1):113–170. doi:10.1002/cphy.c160005
10. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes*. 2005;54(6):1615–1625. doi:10.2337/diabetes.54.6.1615
11. Camici PG, d'Amati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment. *Nat Rev Cardiol*. 2015;12(1):48–62. doi:10.1038/nrcardio.2014.160
12. Esposito R, Galderisi M, De Palma D, et al. Non-invasive assessment of peripheral microvascular function in patients with heart failure. *J Am Soc Echocardiogr*. 2015;28(11):1325–1332. doi:10.1016/j.echo.2015.06.011
13. De Backer D, Ospina-Tascon G, Salgado D, Favory R, Creteur J, Vincent JL. Monitoring the microcirculation in the critically ill patient: current methods and future approaches. *Intensive Care Med*. 2010;36(11):1813–1825. doi:10.1007/s00134-010-2005-3
14. Cutolo M, Sulli A, Smith V. How to perform and interpret capillaroscopy. *Best Pract Res Clin Rheumatol*. 2013;27(2):237–248. doi:10.1016/j.berh.2013.03.001
15. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. *Ann Surg*. 2011;254(2):194–200. doi:10.1097/SLA.0b013e318226113d